Gefitinib-Induced Hepatotoxicity in Patients Treated for Non-Small Cell Lung Cancer

Publisher： Karger

E-ISSN： 2296-5262|35|9|509-513

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.35, Iss.9, 2012-08, pp. : 509-513

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Erlotinib Achieved Partial Response in a Non-Small Cell Lung Cancer Patient with Gefitinib-Induced Interstitial Lung Disease

By  

Case Reports in Oncology, Vol. 4, Iss. 3, 2011-09 ,pp. : 464-466

Karger

Access to resources Recommend Favorite

Phase II Study of Gefitinib Readministration in Patients with Advanced Non-Small Cell Lung Cancer and Previous Response to Gefitinib

By  

Oncology, Vol. 79, Iss. 5-6, 2011-04 ,pp. : 423-429

Karger

Access to resources Recommend Favorite

Prognostic Factors for Gefitinib-Treated Postoperative Recurrence in Non-Small Cell Lung Cancer

By  

Oncology, Vol. 72, Iss. 3-4, 2008-01 ,pp. : 234-242

Karger

Access to resources Recommend Favorite

Comparison of the Efficacy of Gefitinib in Patients with Non-Small Cell Lung Cancer according to the Type of Epidermal Growth Factor Receptor Mutation

By  

Oncology, Vol. 87, Iss. 4, 2014-07 ,pp. : 215-223

Karger

Access to resources Recommend Favorite

Comparison of Survival in Advanced Non-Small Cell Lung Cancer Patients in the Pre- and Post-Gefitinib Eras

By  

Oncology, Vol. 76, Iss. 4, 2009-02 ,pp. : 239-246

Karger

Access to resources Recommend Favorite